Malignant Pleural Mesothelioma - Pipeline Review, H1 2015

Published: May, 2015 | Pages: 199 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Malignant Pleural Mesothelioma - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Malignant Pleural Mesothelioma - Pipeline Review, H1 2015', provides an overview of the Malignant Pleural Mesothelioma's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Malignant Pleural Mesothelioma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Malignant Pleural Mesothelioma and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Malignant Pleural Mesothelioma
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Malignant Pleural Mesothelioma and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Malignant Pleural Mesothelioma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Malignant Pleural Mesothelioma pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Malignant Pleural Mesothelioma
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Malignant Pleural Mesothelioma pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents

Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Malignant Pleural Mesothelioma Overview 10
Therapeutics Development 11
Pipeline Products for Malignant Pleural Mesothelioma - Overview 11
Pipeline Products for Malignant Pleural Mesothelioma - Comparative Analysis 12
Malignant Pleural Mesothelioma - Therapeutics under Development by Companies 13
Malignant Pleural Mesothelioma - Therapeutics under Investigation by Universities/Institutes 15
Malignant Pleural Mesothelioma - Pipeline Products Glance 16
Late Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Malignant Pleural Mesothelioma - Products under Development by Companies 19
Malignant Pleural Mesothelioma - Products under Investigation by Universities/Institutes 22
Malignant Pleural Mesothelioma - Companies Involved in Therapeutics Development 23
Aduro BioTech, Inc. 23
Advantagene, Inc. 24
Amphera BV 25
Bayer AG 26
Biogen, Inc. 27
Bionomics Limited 28
Boehringer Ingelheim GmbH 29
Boston Biomedical, Inc. 30
Bristol-Myers Squibb Company 31
CanBas Co., Ltd. 32
Concordia Healthcare Corp. 33
EnGeneIC Ltd 34
F. Hoffmann-La Roche Ltd. 35
Five Prime Therapeutics, Inc. 36
Genelux Corporation 37
GlaxoSmithKline plc 38
Juno Therapeutics Inc. 39
MedImmune, LLC 40
Merck & Co., Inc. 41
MolMed S.p.A. 42
Morphotek, Inc. 43
Novartis AG 44
Oxford BioMedica plc 45
Pfizer Inc. 46
Pharma Mar, S.A. 47
Polaris Pharmaceuticals, Inc. 48
Synta Pharmaceuticals Corp. 49
Verastem, Inc. 50
Virttu Biologics Limited 51
Malignant Pleural Mesothelioma - Therapeutics Assessment 52
Assessment by Monotherapy Products 52
Assessment by Target 53
Assessment by Mechanism of Action 55
Assessment by Route of Administration 57
Assessment by Molecule Type 59
Drug Profiles 61
amatuximab - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
anetumab ravtansine - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
ascrinvacumab - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
BG-00001 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
BMS-986148 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
BNC-105 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
CBP-501 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Cell Therapy 1 for Oncology - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
CRS-207 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
defactinib hydrochloride - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
FP-1039 - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
ganetespib - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Gene Therapy for Malignant Pleural Mesothelioma - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Gene Therapy to Activate NK4 for Malignant Pleural Mesothelioma - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
GLONC-1 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
GSK-2256098 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
HSV-1716 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
iCasp9M28z - Drug Profile 91
Product Description 91
Mechanism of Action 91
R&D Progress 91
JTCR-016 - Drug Profile 92
Product Description 92
Mechanism of Action 92
R&D Progress 92
MesoCancerVac - Drug Profile 93
Product Description 93
Mechanism of Action 93
R&D Progress 93
MesoCART - Drug Profile 94
Product Description 94
Mechanism of Action 94
R&D Progress 94
Monoclonal Antibody Conjugated to Target Mesothelin for Oncology - Drug Profile 95
Product Description 95
Mechanism of Action 95
R&D Progress 95
napabucasin - Drug Profile 97
Product Description 97
Mechanism of Action 97
R&D Progress 97
NGR-hTNF - Drug Profile 100
Product Description 100
Mechanism of Action 100
R&D Progress 100
nintedanib - Drug Profile 104
Product Description 104
Mechanism of Action 104
R&D Progress 104
pegargiminase - Drug Profile 108
Product Description 108
Mechanism of Action 108
R&D Progress 108
pembrolizumab - Drug Profile 111
Product Description 111
Mechanism of Action 111
R&D Progress 111
porfimer sodium - Drug Profile 118
Product Description 118
Mechanism of Action 118
R&D Progress 118
RG-7787 - Drug Profile 119
Product Description 119
Mechanism of Action 119
R&D Progress 119
Stem Cell Therapy to Target TRAIL Receptor for Malignant Pleural Mesothelioma and Mestatic Lung Cancer - Drug Profile 120
Product Description 120
Mechanism of Action 120
R&D Progress 120
TargomiRs - Drug Profile 121
Product Description 121
Mechanism of Action 121
R&D Progress 121
trabectedin - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
tremelimumab - Drug Profile 127
Product Description 127
Mechanism of Action 127
R&D Progress 127
TroVax - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
Vaccine For Oncolytic Newcastle Disease Virus - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
VS-5584 - Drug Profile 133
Product Description 133
Mechanism of Action 133
R&D Progress 133
Malignant Pleural Mesothelioma - Recent Pipeline Updates 135
Malignant Pleural Mesothelioma - Dormant Projects 187
Malignant Pleural Mesothelioma - Discontinued Products 188
Malignant Pleural Mesothelioma - Product Development Milestones 189
Featured News & Press Releases 189
May 14, 2015: PharmaMar announces new advances in oncology at ASCO 2015 for its compound YONDELIS in small cell lung cancer, soft tissue sarcoma, and mesothelioma 189
Apr 23, 2015: Mesothelioma Immunotherapy Vaccine Receives Orphan Drug Designation from FDA, Baron & Budd Reports 190
Apr 19, 2015: Early Findings with KEYTRUDA (pembrolizumab), Merck's Anti-PD-1 Therapy, in Patients with Advanced Pleural Mesothelioma Presented at AACR Annual Meeting 190
Apr 19, 2015: Immunotherapy drug pembrolizumab shows promise for mesothelioma patients 191
Mar 26, 2015: Aduro Receives Orphan Drug Designation for CRS-207 in Mesothelioma 192
Mar 18, 2015: New Data Investigating Merck's KEYTRUDA (pembrolizumab) in Advanced Non-Small Cell Lung Cancer and Mesothelioma to Be Presented in Clinical Trials Plenary Session at AACR 2015 192
Jan 20, 2015: Verastem Doses First Patient In Phase 1 Clinical Trial Evaluating VS-5584 In Combination With VS-6063 In Mesothelioma 194
Jan 20, 2015: Verastem Receives Orphan Medicinal Product Designation from the European Commission for VS-5584 in Mesothelioma 194
Dec 18, 2014: Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Receives Orphan Drug Designation in the United States and the European Union for the Treatment of Malignant Pleural Mesothelioma 195
Oct 24, 2014: Verastem Presents New Data on Mesothelioma Programs at the 12th International Mesothelioma Interest Group Meeting 195
Appendix 198
Methodology 198
Coverage 198
Secondary Research 198
Primary Research 198
Expert Panel Validation 198
Contact Us 198
Disclaimer 199

List of Tables

Number of Products under Development for Malignant Pleural Mesothelioma, H1 2015 11
Number of Products under Development for Malignant Pleural Mesothelioma - Comparative Analysis, H1 2015 12
Number of Products under Development by Companies, H1 2015 14
Number of Products under Investigation by Universities/Institutes, H1 2015 15
Comparative Analysis by Late Stage Development, H1 2015 16
Comparative Analysis by Clinical Stage Development, H1 2015 17
Comparative Analysis by Early Stage Development, H1 2015 18
Products under Development by Companies, H1 2015 19
Products under Development by Companies, H1 2015 (Contd..1) 20
Products under Development by Companies, H1 2015 (Contd..2) 21
Products under Investigation by Universities/Institutes, H1 2015 22
Malignant Pleural Mesothelioma - Pipeline by Aduro BioTech, Inc., H1 2015 23
Malignant Pleural Mesothelioma - Pipeline by Advantagene, Inc., H1 2015 24
Malignant Pleural Mesothelioma - Pipeline by Amphera BV, H1 2015 25
Malignant Pleural Mesothelioma - Pipeline by Bayer AG, H1 2015 26
Malignant Pleural Mesothelioma - Pipeline by Biogen, Inc., H1 2015 27
Malignant Pleural Mesothelioma - Pipeline by Bionomics Limited, H1 2015 28
Malignant Pleural Mesothelioma - Pipeline by Boehringer Ingelheim GmbH, H1 2015 29
Malignant Pleural Mesothelioma - Pipeline by Boston Biomedical, Inc., H1 2015 30
Malignant Pleural Mesothelioma - Pipeline by Bristol-Myers Squibb Company, H1 2015 31
Malignant Pleural Mesothelioma - Pipeline by CanBas Co., Ltd., H1 2015 32
Malignant Pleural Mesothelioma - Pipeline by Concordia Healthcare Corp., H1 2015 33
Malignant Pleural Mesothelioma - Pipeline by EnGeneIC Ltd, H1 2015 34
Malignant Pleural Mesothelioma - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 35
Malignant Pleural Mesothelioma - Pipeline by Five Prime Therapeutics, Inc., H1 2015 36
Malignant Pleural Mesothelioma - Pipeline by Genelux Corporation, H1 2015 37
Malignant Pleural Mesothelioma - Pipeline by GlaxoSmithKline plc, H1 2015 38
Malignant Pleural Mesothelioma - Pipeline by Juno Therapeutics Inc., H1 2015 39
Malignant Pleural Mesothelioma - Pipeline by MedImmune, LLC, H1 2015 40
Malignant Pleural Mesothelioma - Pipeline by Merck & Co., Inc., H1 2015 41
Malignant Pleural Mesothelioma - Pipeline by MolMed S.p.A., H1 2015 42
Malignant Pleural Mesothelioma - Pipeline by Morphotek, Inc., H1 2015 43
Malignant Pleural Mesothelioma - Pipeline by Novartis AG, H1 2015 44
Malignant Pleural Mesothelioma - Pipeline by Oxford BioMedica plc, H1 2015 45
Malignant Pleural Mesothelioma - Pipeline by Pfizer Inc., H1 2015 46
Malignant Pleural Mesothelioma - Pipeline by Pharma Mar, S.A., H1 2015 47
Malignant Pleural Mesothelioma - Pipeline by Polaris Pharmaceuticals, Inc., H1 2015 48
Malignant Pleural Mesothelioma - Pipeline by Synta Pharmaceuticals Corp., H1 2015 49
Malignant Pleural Mesothelioma - Pipeline by Verastem, Inc., H1 2015 50
Malignant Pleural Mesothelioma - Pipeline by Virttu Biologics Limited, H1 2015 51
Assessment by Monotherapy Products, H1 2015 52
Number of Products by Stage and Target, H1 2015 54
Number of Products by Stage and Mechanism of Action, H1 2015 56
Number of Products by Stage and Route of Administration, H1 2015 58
Number of Products by Stage and Molecule Type, H1 2015 60
Malignant Pleural Mesothelioma Therapeutics - Recent Pipeline Updates, H1 2015 135
Malignant Pleural Mesothelioma - Dormant Projects, H1 2015 187
Malignant Pleural Mesothelioma - Discontinued Products, H1 2015 188